CRISPR, a gene-editing tool, has demonstrated significant success in a phase-1 trial, reducing blood cholesterol levels by over 50%. CRISPR Therapeutics CEO Dr. Sam Kulkarni projects market release within five years, potentially aiding India's high cardiovascular disease rates. Doctors express optimism, though widespread application remains several years off.